Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension
Recruiting · NCT05566002 · Observational (researchers observe without assigning treatment) · Lead sponsor: Chinese Pulmonary Vascular Disease Research Group
View the official record on ClinicalTrials.gov →Interventions studied
Right heart catheterization
What this trial is about
Pulmonary hypertension represents a challenging and heterogeneous condition that is associated with high mortality and morbidity if left untreated. Artificial intelligence is used to study and develop theories and methods that simulate and extend human intelligence, which is being applied in fields related to cardiovascular diseases. The study intends to combine multimodal clinical data of patients who undergo right heart catheterization at Fuwai Hospital with artificial intelligence techniques to create programs that can screen and diagnose pulmonary hypertension.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Age ≥18 years old
- Patients previously received chest X-ray, electrocardiography, echocardiography, other routine examinations, and RHC at the Fuwai Hospital, CAMS \& PUMC, Beijing, China
Exclusion criteria
- Patients without RHC
- The quality of routine examinations and RHC cannot meet the requirement for further analysis
- Severe loss of results of routine examinations (chest X-ray, electrocardiography, echocardiography, etc.)
Where it is running
1 location listed.
- Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College - Beijing, Beijing Municipality, China